SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron (GERN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: (no name provided) who wrote (15)1/10/1997 11:37:00 PM
From: scaram(o)uche   of 50
 
If you're missing something, I don't see it. I do believe, however, that there is a renewed premium that will be placed on good science, and that companies will no longer languish with full patent portfolios and market caps of 50 million. So, I do think the down side is somewhat limited.

A short would also run the risk that the "I'll buy anthing ass'd with aging" crowd, the melatonin freaks et al., will find it and drive it. Telomere shortening for cancer and the skin senescence programs are super-hypable, and the proprietary position is clearly theirs.

I have a tough time shorting good science. You do it, and I'll congratulate you if it works. I haven't got the guts. :-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News